Zantac Lawsuit

You may have heard in the news that Zantac (ranitidine) has been linked to cancer. Lawsuits against Zantac manufacturers allege the drug contains a cancer-causing chemical called N-Nitrosodimethylamine (NDMA).

The law firm of Baum Hedlund Aristei & Goldman represents people from across the country in personal injury and wrongful death Zantac lawsuits. We intend to hold the drug makers accountable for allegedly concealing the Zantac cancer link and putting profit before people.

IMPORTANT ZANTAC UPDATE: The U.S. Food and Drug Administration announced on April 1, 2020 that it is requesting manufacturers to withdraw all Zantac and generic Zantac OTC ranitidine drugs from the market effective immediately. The FDA determined that N-Nitrosodimethylamine (NDMA) in some ranitidine medications “increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels…” The FDA, the Environmental Protection Agency (EPA), and the World Health Organization (WHO) all classify NDMA as a cancer-causing substance.

What is Zantac?

Chemically known as ranitidine hydrochloride, Zantac (ranitidine) belongs to a class of drugs called histamine H2-receptor antagonists (or H2 blockers), which decrease the amount of acid produced by the stomach.

Zantac is a very popular antacid medication that has been on the market since the early 1980s. Zantac is available over the counter (Zantac OTC) and by prescription. People commonly use Zantac for acid reflux, heartburn, and a host of other stomach, throat, and gastrointestinal issues. Others use Zantac for allergies to supplement their treatment regimen.

Zantac dosage varies between 75 and 150 mg tablets, though some patients take a once daily Zantac 300 mg dosage.

Since the 1980s, numerous studies have demonstrated a link between the NDMA in Zantac and cancer. Mounting evidence also allegedly shows that Sanofi and Boehringer Ingelheim, the big pharma companies that make Zantac (ranitidine hydrochloride), concealed the Zantac cancer link from millions of people who took the drug for heartburn, gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), sour stomach, Barrett’s esophagus, acid reflux, and other issues. This deception came as the companies made unprecedented profits from Zantac, the first drug to generate $1 billion in sales.


Ranitidine in the News

The U.S. Food and Drug Administration (FDA) announced on September 13, 2019 that it is investigating Zantac cancer risks after testing of Zantac 150 tablets found the commonly-used heartburn medication contains NDMA at levels up to 3,000 times greater than the FDA’s daily intake limit. The Zantac cancer lawyers at Baum Hedlund Aristei & Goldman believe there is no safe level of NDMA. 

With countless people now stricken with cancer after taking Zantac, many are turning to the courts and filing a Zantac lawsuit to hold Sanofi and Boehringer Ingelheim accountable for their reckless disregard for human health and willingness to put profit over people.

On April 1, 2020, the FDA  issued an immediate market withdrawal request of all Zantac (ranitidine) products after determining that NDMA in “some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels…”

Prior to the FDA market withdrawal of ranitidine, numerous manufacturers issued generic Zantac recalls on their own, including Apotex, Sandoz (Novartis), and GlaxoSmithKline (GSK) after Valisure, an online pharmacy that batch tests the medications it sells, and Emery Pharma, a contract laboratory, found unacceptably high levels of NDMA in ranitidine during testing. Both filed citizen’s petitions with the FDA, urging the agency to suspend sales and issue a Zantac recall. Some versions of Zantac were also recalled in Canada and Europe.

Join the Zantac Lawsuit

If you took Zantac and developed cancer, it is in your best interest to speak with an experienced personal injury attorney about filing a Zantac lawsuit. Attorneys from the law firm of Baum Hedlund Aristei & Goldman have vast experience holding big corporations accountable for concealing the true dangers of consumer products. Across all areas of practice, the firm has obtained more than $4 billion in verdicts and settlements on behalf of clients.

Zantac Cancer Lawyer

In 2018 and 2019, Baum Hedlund Aristei & Goldman attorney R. Brent Wisner served as co-lead trial counsel in two of the first three glyphosate cancer cases to go to trial.

One of these cases resulted in a $2.055 billion verdict for our clients, the second-largest personal injury verdict in the nation in 2019, and the ninth-largest personal injury verdict in American history. Another case resulted in a $289.2 million verdict on behalf of our client, the second-largest jury verdict in the state of California for 2018.

zantac cancer wisner quote

On Feb. 24, 2020, the judge overseeing the Zantac MDL (federal multi-district litigation) appointed Brent to the Practices and Procedures team to help establish the protocols and methodology for litigating the tens of thousands of cases to be filed in the months and years to come.

Brent also serves as Co-Chair of the Zantac Litigation Group for American Association for Justice and has been invited to deliver numerous Zantac presentations at prestigious national lawyer conferences across the nation.

Baum Hedlund Aristei & Goldman knows how to win big cases against big companies. Our track record of success—which goes back over 40 years—speaks for itself. If you developed cancer after taking Zantac, call us today for a free Zantac lawsuit evaluation.

Zantac lawsuit cancer attorney

June 8, 2020 – Alameda County, California – – Baum Hedlund Aristei & Goldman and the Moore Law Group have filed lawsuits on behalf of 40 cancer victims and their families alleging the manufacturers of Zantac (ranitidine) have known since the early 1980s that ingestion of the widely-used heartburn medication leads to the production of “staggering amounts” of a potent carcinogen. Attorneys R. Brent Wisner of Baum Hedlund and Jennifer Moore of the Moore Law Group spearheaded the trials in the Roundup litigation, and they intend to repeat that success here for their 7,600+ clients.

The complaints allege the manufacturers caused severe injuries to each of the plaintiffs by manufacturing defective and dangerous drugs that have no business being in a human body, conducted rigged studies to conceal the Zantac-NDMA link to the FDA and lack labels that properly warn consumers of the dangers associated with Zantac (ranitidine) use.

Among the plaintiffs is Hanna Carbajal, a California mother who alleges that her ingestion of brand name Zantac while pregnant—the first prescription drug in history to reach $1 billion in sales—caused her 8-year-old son to develop testicular cancer at the age of five.

The other plaintiffs allege exposure to brand-name and/or generic over-the-counter (OTC) Zantac (ranitidine) caused them to develop bladder cancer, kidney cancer, prostate cancer, testicular cancer, and thyroid cancer.

The defendants named in each complaint vary based on the drug (or drugs) the plaintiffs ingested. Some of the plaintiffs took generic over-the-counter (“OTC”) Zantac, others took prescription Zantac, and some took a combination of prescription and generic versions of the drug. GlaxoSmithKline (GSK), the company responsible for designing and developing Zantac, is named in every complaint. The complaints collectively list six manufacturer defendants:

  • GlaxoSmithKline, LLC, of Philadelphia, PA
  • Boehringer Ingelheim Pharmaceuticals, Inc. of Ridgefield, CT
  • Boehringer Ingelheim USA Corporation of Ridgefield, CT
  • Pfizer, Inc. of New York, NY
  • Sanofi US Services Inc. of Bridgewater, NJ
  • Sanofi-Aventis U.S., LLC of Bridgewater, NJ

The complaints allege seven causes of action and seek punitive damages against the manufacturer defendants:

Count I: Strict Products Liability – Failure to Warn

Count II: Strict Products Liability – Manufacturing Defect

Count III: Negligence – Failure to Warn

Count IV: Negligent Product Design

Count V: Negligent Manufacturing

Count VI: Negligent Misrepresentation

Count VII: Negligence

Attorneys R. Brent Wisner, Michael L. Baum, Pedram Esfandiary, Adam M. Foster, and Nicole K.H. Maldonado from Baum Hedlund Aristei & Goldman, and Jennifer Moore, Andie B. Camden, and Ashton R. Smith from the Moore Law Group, filed the complaints in Alameda County Superior Court on behalf of 40 plaintiffs, the first group of Zantac cancer victims yet to be filed in California state court.

The legal team also submitted a petition today to formally consolidate the cases in a Judicial Council Coordinated Proceeding (JCCP).

A JCCP is similar to a federal multidistrict litigation (MDL); both provide unified management for the pretrial and trial phases of consolidated cases. In the federal Zantac MDL (In Re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, 20-MD-2924), U.S. District Court for the Southern District of Florida, plaintiffs have already filed at least 230 complaints, and many thousands more are preparing to file cases in federal court and courts throughout the country.

Ms. Moore and Mr. Wisner both participated in forming the MDL in January 2020 and now, here in California, seek to create the same type of coordinated proceeding. Mr. Wisner explains, “We did the same thing during the Roundup litigation. We created both an MDL and JCCP.  And, while Ms. Moore took the lead in trying the first federal case in the MDL, I took the lead in state court. Together, we were able to obtain over $2.4 billion in verdicts. We plan to dwarf that here in this Zantac litigation.”  Ms. Moore agrees, “Coordinating these two important proceedings is the first step in putting pressure on these defendants to come to the negotiating table and do right by our clients. I am looking forward to getting a case to trial in California state court as soon as possible.”

Details about the Allegations, the Plaintiffs and the Legal Team

Zantac History and NDMA Controversy

Zantac (ranitidine) was originally discovered and developed by scientist John Bradshaw on behalf of GSK in 1976. The drug gained approval from the U.S. Food and Drug Administration (FDA) in 1983 and quickly became one of GSK’s most successful products. Since the 1990s, several companies, including Pfizer, Boehringer Ingelheim, and Sanofi (and their respective subsidiaries) have controlled the generic rights to sell OTC ranitidine. According to GSK’s 2019 annual report, the drugmaker “discontinued making and selling prescription Zantac tablets in 2017 … in the U.S.”

In September of 2019, pharmacy and testing laboratory Valisure filed a Citizen Petition calling for the recall of all ranitidine-containing products due to exceedingly high levels of N- Nitrosodimethylamine (NDMA), a potent carcinogen found during testing of ranitidine pills. The U.S. Food and Drug Administration and European regulators started reviewing the safety of ranitidine with a specific focus on the presence of NDMA.

Discovered as a bi-product in manufacturing rocket fuel, NDMA is only used to induce tumors in animals as part of laboratory experiments. NDMA’s only function is to cause cancer, and according to the complaints, the NDMA in ranitidine is not caused by any direct contamination. Rather, the ranitidine molecule itself contains the constituent molecules to form NDMA.

Valisure’s finding and Citizen Petition triggered a cascade of recalls by ranitidine manufacturers and retailers. In January of 2020, research laboratory Emery Pharma submitted another Citizen Petition to the FDA, showing that NDMA accumulates in ranitidine at unsafe rates when exposed to heat levels that would occur during transport and storage. According to Emery Pharma’s Citizen Petition, ranitidine is a time-and temperature-sensitive pharmaceutical product that develops NDMA when exposed to heat, a common occurrence during shipping, handling, and storage. In addition to warning about this condition, Emery Pharma requested agency directives to manufacturers and distributors to ship ranitidine medications in temperature-controlled vehicles.

In response, on April 1, 2020, the FDA requested drug manufacturers to withdraw all Zantac and generic ranitidine drugs from the market effective immediately after determining that levels of NDMA in some ranitidine medications “increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels…”

The FDA, in effect, issued a public statement requesting the immediate removal of all ranitidine medications from the market due to the risk to public health:

“The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity.” Based upon its own testing and evaluation, the FDA concluded that “NDMA levels increase in ranitidine even under normal storage conditions and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers.”

According to the complaints, the FDA’s testing of ranitidine confirms that NDMA levels increase in the drug even under normal storage conditions, and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures to which ranitidine may be exposed during distribution and handling by consumers.

Zantac Manufacturers Have Known Since the Early 1980s That Ranitidine Ingestion Leads to the Formation of NDMA

In 1981, research published in The Lancet found that ranitidine turned into mutagenic N-nitroso compounds (of which NDMA is one) in human gastric fluid when accompanied by nitrites (a chemical commonly found in heartburn-inducing foods). Based on the findings, one of the researchers cautioned that, in the context of ranitidine ingestion, “it would seem prudent to … suggest[] a diet low in nitrates and nitrites, by asking patients not to take these at times close to (or with) meals[.]”

According to the complaints, GSK knew about this study and “attempted to discredit it.”

Other early studies, including one conducted by GSK in the early 1980s, demonstrated that NDMA formed when ranitidine was exposed to heat. In the study, which was presented to the FDA, GSK remarkably admitted that ranitidine use caused the proliferation of bacteria in the human stomach that are known to convert nitrates to nitrites, which leads to elevated levels of nitrite in the stomach environment. GSK acknowledged this could increase the risk of developing NDMA and, in turn, cancer, but then dismissed this risk because people were only expected to use ranitidine-containing products for a short-term period:

“Ranitidine is recommended only for short-term use and carcinogenic risk, if any, should thus be minimized.”

After numerous studies raised concerns over the link between Zantac and the formation of NDMA, GSK published a clinical study in 1987 specifically investigating gastric contents in human patients and N-nitroso compounds. While the study indicated that there were no elevated levels of N-nitroso compounds (of which NDMA is one), the complaints allege it was intentionally “rigged to fail,” and “designed to mask any potential cancer risk.”

“[I]n the testing it did do, GSK refused to test gastric samples that contained ranitidine in them out of concern that samples with ranitidine would contain ‘high concentrations of N-nitroso compounds being recorded’,” the complaints read. “So, GSK did not test for NDMA in any gastric fluid that contained ranitidine.”

“It appears GSK’s clinical study was rigged and purposely failed to investigate the connection between ranitidine ingestion and the formation of NDMA, which was the well-established at the time,” said Jennifer Moore, attorney for the plaintiffs. “The FDA never would have approved the drug if GSK had tested it properly.”

“GSK admitted decades ago that Zantac could react with nitrite in the stomach to form NDMA, and that long-term use of Zantac could lead to elevated levels of nitrite in the human stomach,” stated R. Brent Wisner. “It’s unconscionable that this didn’t stop them from telling millions of people through advertising to take Zantac when consuming foods containing high levels of nitrates, like hotdogs and pepperoni pizza. Their failure to tell the FDA, the medical community, and their consumers about the true risks associated with this drug has created an epidemic of cancer.”

GSK and Other Manufacturers Disregarded Scientific Evidence Linking Ranitidine to Cancer, Never Reported Safety Data to FDA

Manufacturers of an approved drug are required to submit an annual report to the FDA containing, among other things, new information regarding the drug’s safety. Since the early 1980s numerous animal and epidemiological studies have found the ingestion of ranitidine can lead to the production of NDMA.

In 2016, researchers at Stanford University conducted an experiment in which they measured NDMA in the urine of healthy individuals over the course of 24 hours, administered one dose of ranitidine, and then measured the NDMA in the urine of the same individuals for another 24 hours. On average, the level of NDMA increased by 400 times, to approximately 47,000 nanograms. According to the study, unsafe levels of NDMA are formed in the human body as a result of ranitidine ingestion. The scientists further explained that humans do not typically excrete NDMA in their urine, so that the observed 47,000 nanograms likely only captured 1/100 of the actual NDMA levels in the human body.

Despite regulations requiring  drugmakers to submit “copies of unpublished reports and summaries of published reports of new toxicological findings in animal studies and in vitro studies (e.g., mutagenicity) conducted by, or otherwise obtained by, the [manufacturer] concerning the ingredients in the drug product,” the defendants ignored the regulations, disregarded the scientific evidence, and did not report to the FDA significant new information affecting the safety of ranitidine drugs, according to the allegations.

Punitive Damages Sought for “Conscious Disregard” of Plaintiffs’ Rights

The 40 plaintiffs allege the manufacturers of Zantac and generic ranitidine knew they could profit by convincing consumers that ranitidine was harmless to humans, and that full disclosure of the drug’s true risks would have limited the amount of money they could generate. According to the complaints, the defendants accomplished this through a misleading label, a comprehensive scheme of selective misleading research and testing, false advertising, and deceptive omissions. As a result of the defendants’ conscious disregard for their rights, the plaintiffs have requested punitive damages against the drug manufacturers.

The Zantac Plaintiffs

The plaintiffs are all California residents aged 8 to 67 years. A number of plaintiffs granted permission to be mentioned in this press release:

Grag Amelino, El Segundo
Michael Caratti, Fair Oaks
Hanna Carbajal, Valley Springs
Brian Elias, Covina
Marc Friedland, Palmdale
James Goetz, Redondo Beach
David Harbaugh, Pasadena
Christopher Ives, Sonora
Marc Mitchell, Santa Rosa
Mark Morrison, Napa
Albert Muesse, Stanton
James Newton, Vallejo
Dwight Norman Sr., Stockton
Lynn Smith, Milpitas
Brian Wilbur, El Cajon

The cases were manually filed on May 11, but due to delays brought on by the COVID-19 pandemic, the court was unable to issue case numbers until the second and third weeks of May. Case numbers:

RG20061276, RG20061309, RG20061342, RG20061365, RG20061371, RG20061398, RG20061402, RG20061406, RG20061430, RG20061439, RG20061448, RG20061460, RG20061466, RG20061472, RG20061519, RG20061524, RG20061529, RG20061536, RG20061561, RG20061567, , RG20061576, RG20061592, RG20061597, RG20061599, RG20061603, RG20061631, RG20061644, RG20061652, RG20061667, RG20061681, RG20061688, RG20061705, RG20061712, RG20061726, RG20061739, RG20061766, RG20061771, RG20061782, RG20061791, RG20061977

Zantac Cancer Plaintiff: Hanna Carbajal on Behalf of Her Minor Son

Hanna Carbajal took OTC Zantac while she was pregnant with her son between 2010 and 2011. For many years, Zantac and its generic equivalents have been marketed to pregnant women as a safe treatment for heartburn. Prior to the FDA’s April 2020 market withdrawal request, the agency considered the drug as Category B, safe to take during pregnancy.

However, prevailing scientific evidence has found that exposure to ranitidine (and the attendant NDMA) can cause testicular cancer. NDMA is, itself, a very small molecule. This allows it to freely pass through all areas of the body, including the blood-brain and placental barrier. This is particularly concerning as ranitidine has been marketed safe for pregnant women and young children for years, including prior to and during the time Ms. Carbajal ingested the drug.

According to the complaint, as a direct result of being exposed to carcinogenic ranitidine-containing drugs in utero, Ms. Carbajal’s minor son was diagnosed with testicular cancer. Had the defendants warned Ms. Carbajal or any of the plaintiffs that ranitidine could lead to the production of NDMA or cancer, they never would have taken the medication.

As a result of exposure to ranitidine, Ms. Carbajal’s son has suffered significant injuries, including testicular cancer, that has required surgeries to remove a testicle, chemotherapy, and other treatments to address the physical effects and permanent damage.

Zantac Cancer Plaintiff: Brian Wilbur

Brian WilburBrian Wilbur, a pillar in his community, has spent 37 years in the California school system. For the last 23 years, he has been the school administrator / Director of Extended Curricular Programs at Grossmont Union High School District in El Cajon, California, where he also served for 11 years as a high school principle. Prior to that he was a teacher for 13 years.

In 2009, Mr. Wilbur was prescribed brand-name Zantac to address stomach issues and later took generic ranitidine.

In 2017, Mr. Wilbur was diagnosed with prostate cancer after taking prescription Zantac and ranitidine for roughly seven years. He was forced to undergo radiation therapy and medication to treat his prostate cancer.

According to Mr. Wilbur’s complaint, an epidemiological study looking at various cancer risks and H2 blockers, including ranitidine, showed that ranitidine consumption increased the risk of prostate, lung, esophageal, pancreatic, and kidney cancer. Of particular note, the study indicated that people under the age of 60 that took ranitidine were five times more likely to contract prostate cancer.

Mr. Wilbur never would have taken ranitidine drugs if the defendants had warned about the known dangers.

Baum Hedlund Aristei & Goldman

Baum, Hedlund, Aristei & Goldman has resolved thousands of cases across many practice areas and won more than $4 billion in verdicts and settlements over the past 40 years. The firm’s award-winning personal injury attorneys have extensive experience holding large corporations accountable for concealing the dangers of consumer products. The National Law Journal and The Trial Lawyer Magazine awarded the firm’s Roundup cancer legal team (all of whom are working on the Zantac cases) with 2020 Elite Trial Lawyers Mass Tort Law Firm of the Year finalists, 2019 Elite Trial Lawyers Mass Tort Trial Team of the Year winner, and Trial Team of the Year 2019 by The National Trial Lawyers Top 100.

R. Brent Wisner, vice president and partner of Baum Hedlund, is the lead trial attorney for the firm’s Zantac cancer litigation and Roundup cancer litigation. He co-led two of the three Roundup cancer trials against Monsanto, obtaining the largest verdict in California in 2019 and the ninth largest verdict in US history with the $2B verdict for the Pilliods. He has won numerous awards and recognition, including 2019 Civil Plaintiff Trial Lawyer of the Year, by the National Trial Lawyers and American Lawyer Media; America’s Most Influential Trial Lawyers by The National Law Journal and Trial Lawyer Magazine and 2019 Winning Litigators, Titans of Industry by The National Law Journal.

In early 2020, U.S. District Court Judge Robin L. Rosenberg, who oversees all Zantac cancer cases litigation in the MDL, appointed Brent to the Practices and Procedures team, a small group of lawyers who helped establish the protocols and methodology for litigating the tens of thousands of Zantac cases expected to be filed. Judge Rosenberg also originally appointed Brent to the Plaintiffs’ Steering Committee and as Co-Chair of the Trial and Bellwether Committee in the MDL, but Brent recently resigned from those positions to focus his efforts on the California litigation. Brent also serves as Co-Chair of the Zantac Litigation Group for American Association For Justice. Since October of 2019, Brent has delivered Zantac presentations both in person and online, for many prestigious national lawyer conferences.

Moore Law Group

The attorneys at Moore Law Group have made a firm commitment to the practice of personal injury law, representing people who have been injured by the carelessness or neglect of corporations, hospitals, or individuals. Led by trial lawyer Jennifer A. Moore, the firm has a track record of success handling complex injury claims.

Jennifer A. Moore, is the founder and owner of Moore Law Group, based in Louisville, Kentucky. She has successfully led numerous class action and complex litigation cases in both state and federal courts. She successfully tried the first MDL Roundup cancer trial, resulting in an $80M verdict against Monsanto. She is admitted to practice in Kentucky and California and has been recognized by Business First as one of Louisville’s Top 40 Under 40 and recently received the University of Kentucky College of Law’s Professional Achievement Award for her work representing cancer victims in the Roundup litigation. Jennifer serves on the Board of Governors for the American Association for Justice (AAJ) and also on AAJ’s National Finance Council, the Section and Litigation Group Leaders Council and Litigation Group Leaders Council. She is a regular speaker at national lawyer conventions and conferences on the Zantac litigation. Along with Mr. Wisner, she serves as co-chair of AAJ’s Zantac Litigation Group.

Zantac Recall

In response to the September 2019 FDA announcement, retailers like CVS and Walgreens pulled Zantac and Zantac over-the-counter generics from their shelves, citing the link between Zantac NDMA and cancer. In statements, both pharmacy companies noted that consumers who purchased the drugs could get Zantac refunds. Generic drug makers like GlaxoSmithKline (GSK), Sandoz, and Apotex have also recalled its ranitidine hydrochloride products.

In October of 2019, Sanofi announced a Zantac recall of its own in the United States and Canada, and the U.K. unit of Teva Pharmaceuticals, the largest generic drug maker in the world, recalled batches of ranitidine.

At least 22 countries have either banned, halted shipping of, or recalled ranitidine hcl. Four other countries have issued warnings and/or launched their own investigations, according to the news media.

In 2018, several companies issued recalls for blood pressure medications that contained levels of NDMA that exceeded FDA limits. However, the levels of NDMA found in these products paled in comparison to that of Zantac.

Zantac Side Effects

The link between Zantac and cancer goes back decades. Our firm represents people from across the country with the following Zantac side effects:

  • Bladder cancer
  • Brain cancer
  • Breast cancer
  • Esophageal/nasal/throat cancer
  • Intestinal cancer
  • Kidney cancer
  • Liver cancer
  • Lung cancer (for non-smokers)
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Stomach cancer
  • Testicular cancer
  • Thyroid cancer
  • Uterine cancer

Other ranitidine Zantac side effects include headaches, abdominal discomfort, nausea and vomiting.

Common Zantac Brands | Products That Contain Ranitidine

Below are some of the most common Zantac brands and generic ranitidine brand names:

  • Zantac 150 Tablets
  • Zantac 150 Maximum Strength
  • Zantac 150 Maximum Strength Cool Mint
  • Zantac 75 Tablets
  • Wal-Zan 150
  • Wal-Zan 75
  • Heartburn Relief (ranitidine)
  • Acid Reducer (ranitidine)
  • Acid Control (ranitidine)

“We have an epidemic of cancer in our society. For years we have been trying to figure out what’s behind it. Our firm has done a lot of work exposing the causes of non-Hodgkin lymphoma in our Monsanto Roundup litigation. Now we have another source of cancer – it appears that for decades, Zantac has been causing cancer, and we’re only now just seeing it. People from all across the country have cancer today because they took Zantac. That is a wrong that we will fight to make right.” – R. Brent Wisner

Zantac Cancer Lawsuit FAQs

Is My Zantac Lawsuit Part of a Class Action?

It depends on your claims for damages. For example, if you took Zantac and were diagnosed with some form of cancer (or if a family member took Zantac and was diagnosed with cancer), you may be eligible to file a personal injury lawsuit against the manufacturers of Zantac and/or over-the-counter Zantac (OTC).

An individual personal injury Zantac lawsuit allows people who developed cancer to obtain the maximum possible compensation for their injuries.

Conversely, if you took Zantac and never developed cancer, you could still seek compensation by filing a class action lawsuit against the makers of prescription Zantac and/or Zantac OTC. A Zantac class action lawsuit allows consumers who purchased prescription Zantac or generic Zantac (ranitidine) to recover the money spent on purchasing the medication.

What is the Difference Between a Zantac Class Action Lawsuit and a Zantac Cancer Lawsuit?

A Zantac class action lawsuit allows consumers who bought Zantac (ranitidine hcl) to recover the money they spent making that purchase, based on allegations that the manufacturer failed to warn about the risk of NDMA cancer. The makers of Zantac made money by concealing the risks of dangerous Zantac side effects and should be held accountable for misleading consumers about the risk of such side effects.

These class action lawsuits can be filed on behalf of anyone who purchased Zantac and has not developed cancer, but wants to hold the makers accountable for profiting from misleading information.

Zantac personal injury or Zantac wrongful death lawsuits are filed by individuals (or their family members) who developed cancer after taking Zantac. Filing an individual personal injury lawsuit allows people who developed cancer to obtain the maximum possible compensation for their injuries. The law on damages varies from state to state, but there are different kinds of damages that the law allows you to receive, such as those for medical bills, lost wages, pain and suffering, loss of past and future earnings, temporary or permanent disability, and any other compensable damages.

Who Can Join the Zantac Class Action Lawsuit?

Anyone who purchased Zantac and can prove they did so may be eligible to participate in a Zantac class action claim. Unlike individual lawsuits against Zantac’s makers, in a class action lawsuit, plaintiffs do not have to prove that they were harmed, only that that they purchased the drug and were not warned about the Zantac cancer risk.

Such plaintiffs argue that they suffered economic losses because they purchased the drug believing it was safe and would not have made that purchase had they known about the risk of life-threatening Zantac adverse effects.

What Will It Cost to Hire a Zantac Attorney?

We provide free Zantac case reviews to anyone who fills out our contact form or calls our offices. It costs you nothing out of pocket to retain our law firm to represent you and pursue justice and compensation on your behalf. We don’t see a dime until we win your case.

Why Are You the Right Law Firm to Handle My Zantac Cancer Lawsuit?

Baum, Hedlund, Aristei & Goldman has earned a reputation for winning big cases against big companies. In practice for nearly 50 years, our firm has obtained more than $4 billion in verdicts and settlements across all areas of practice on behalf of people just like you.

In 2019, Baum Hedlund Aristei & Goldman co-tried a cancer case against one of the largest corporations in the world. We represented a California couple who alleged exposure to a popular herbicide caused them to develop non-Hodgkin lymphoma. After several weeks of trial proceedings, the jury awarded our clients $2.055 billion in damages, the ninth-largest personal injury jury verdict in U.S. history.

Our success isn’t just measured by the financial compensation we bring in on behalf of our clients. We are also committed consumer advocates who work tirelessly to protect people and the environment from harmful products.

The herbicide litigation is an example of our consumer advocacy: for as long as we have been involved in the litigation, we have fought to make public thousands of pages of internal company documents we obtained during discovery to allow people to see what is happening “behind the curtain” of secrecy that normally shrouds ongoing litigation. Why do we do it? Simply put, our firm believes it is a civic duty to share these documents so that the public, media, academics, policymakers, regulators, and others can be better informed, make more informed choices, and use the data to make this world a better place.

If you would like more information on what our firm can do for you, give us a call anytime or fill out the following contact form to schedule a free Zantac lawsuit review.

You Need a Zantac Attorney with a Proven Track Record of Success

Determining liability and proving your case in court can be difficult. To give you and your family the best chance for success, you need a law firm with a winning tradition against major corporations to handle your Zantac lawsuit.

Our trial lawyers know how to win big cases against big companies. If you developed cancer after taking Zantac, call 800-827-0087 today for a free, no-obligation Zantac lawsuit evaluation.

Please complete the contact form below:

* Designates a required field

reCAPTCHA is required.

Please allow a few moments. You will be notified when your information has been received.

Your confidentiality matters. No information, including phone numbers and email addresses will be exchanged, shared or sold to a third party. Any communications to our firm via contact forms, email, phone or U.S. mail, will be treated confidentially. Submissions are made for the purpose of evaluating whether or not our law firm will accept your case and represent you. However, all information contained in your submission will be held confidential. By evaluating your submission we make no representation or agreement to represent you in connection with your claim. Click here to read our Privacy Policy.

Thank you.